Vyne Therapeutics Stock Current Valuation
| VYNE Stock | USD 2.89 0.06 2.12% |
Valuation analysis of Vyne Therapeutics helps investors to measure Vyne Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Vyne Therapeutics' Enterprise Value Multiple is projected to increase significantly based on the last few years of reporting. Fundamental drivers impacting Vyne Therapeutics' valuation include:
Price Book 0.4417 | Enterprise Value -47.6 M | Enterprise Value Ebitda 1.8403 | Price Sales 92.1084 | Enterprise Value Revenue 10.0433 |
Overvalued
Today
Please note that Vyne Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Vyne Therapeutics is based on 3 months time horizon. Increasing Vyne Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Vyne Therapeutics is useful when determining the fair value of the Vyne stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Vyne Therapeutics. Since Vyne Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vyne Stock. However, Vyne Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.89 | Real 2.67 | Target 16.5 | Hype 2.83 | Naive 3.24 |
The real value of Vyne Stock, also known as its intrinsic value, is the underlying worth of Vyne Therapeutics Company, which is reflected in its stock price. It is based on Vyne Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Vyne Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vyne Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vyne Therapeutics helps investors to forecast how Vyne stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vyne Therapeutics more accurately as focusing exclusively on Vyne Therapeutics' fundamentals will not take into account other important factors: Vyne Therapeutics Company Current Valuation Analysis
Vyne Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Vyne Therapeutics Current Valuation | (47.58 M) |
Most of Vyne Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vyne Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Vyne Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Vyne Therapeutics is extremely important. It helps to project a fair market value of Vyne Stock properly, considering its historical fundamentals such as Current Valuation. Since Vyne Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vyne Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vyne Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Vyne Therapeutics has a Current Valuation of (47.58 Million). This is 100.33% lower than that of the Biotechnology sector and 101.02% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.29% higher than that of the company.
Vyne Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vyne Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vyne Therapeutics could also be used in its relative valuation, which is a method of valuing Vyne Therapeutics by comparing valuation metrics of similar companies.Vyne Therapeutics is currently under evaluation in current valuation category among related companies.
Vyne Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vyne Therapeutics from analyzing Vyne Therapeutics' financial statements. These drivers represent accounts that assess Vyne Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vyne Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 157.5M | 204.9M | 52.5M | 8.6M | 9.9M | 9.4M | |
| Enterprise Value | 127.4M | 182.1M | 10.6M | (22.7M) | (26.1M) | (24.8M) |
Vyne Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vyne Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vyne Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Vyne Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (75.31) % | ||||
| Current Valuation | (47.58 M) | ||||
| Shares Outstanding | 14.1 M | ||||
| Shares Owned By Insiders | 8.42 % | ||||
| Shares Owned By Institutions | 57.55 % | ||||
| Number Of Shares Shorted | 81.96 K | ||||
| Price To Book | 0.44 X | ||||
| Price To Sales | 92.11 X | ||||
| Revenue | 424 K | ||||
| Gross Profit | 477 K | ||||
| EBITDA | (29.26 M) | ||||
| Net Income | (27.87 M) | ||||
| Cash And Equivalents | 42.81 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 214 K | ||||
| Current Ratio | 7.60 X | ||||
| Book Value Per Share | 5.83 X | ||||
| Cash Flow From Operations | (25.34 M) | ||||
| Short Ratio | 0.94 X | ||||
| Earnings Per Share | (2.72) X | ||||
| Target Price | 5.58 | ||||
| Number Of Employees | 10 | ||||
| Beta | 1.48 | ||||
| Market Capitalization | 37.64 M | ||||
| Total Asset | 97.69 M | ||||
| Retained Earnings | (691.34 M) | ||||
| Working Capital | 88.42 M | ||||
| Net Asset | 97.69 M |
About Vyne Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vyne Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vyne Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vyne Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:Check out Vyne Therapeutics Piotroski F Score and Vyne Therapeutics Altman Z Score analysis. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Vyne Stock analysis
When running Vyne Therapeutics' price analysis, check to measure Vyne Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vyne Therapeutics is operating at the current time. Most of Vyne Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vyne Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vyne Therapeutics' price. Additionally, you may evaluate how the addition of Vyne Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Vyne Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.72) | Revenue Per Share 0.021 | Quarterly Revenue Growth (0.01) | Return On Assets (0.30) | Return On Equity (0.52) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.